In gastric cancer, we demonstrated for the first time that down-regulation of GLIPR1 inhibited cell proliferation and migration, while up-regulation of GLIPR1 did the opposite and inhibited the cytotoxicity of conventional CAR-T cell, which offered convincing evidence to target GLIPR1 in immunotherapy. The gene discussed is GLIPR1; the disease is gastric cancer.